Research and Development Expenditure
First written in FY2016-Q3. 19 of 31 entries say "Advanced", first in FY2019. Latest entry: 2026-09-11.
54 other companies' latest entry also says "Advanced".
- FY2025-H1AdvancedAnnual report
「The amount of R&D activities for the six-month consolidated period was ¥638 million.」
R&D expenses amounted to ¥638 million, an increase of 32.4% from ¥482 million in the same period of the previous year. - FY2024AdvancedAnnual report
「The Group regards R&D as its highest priority in developing its business and conducts it with 90 R&D staff, including 25 PhD holders, out of a total workforce of 642 (as of 31 July 2024). R&D expenses for the current consolidated fiscal year amounted to ¥978 million, including personnel expenses for R&D staff,」
The number of R&D staff increased from 82 to 90, and R&D expenses increased from ¥840 million to ¥978 million. - FY2024-Q3AdvancedAnnual report
「The amount of R&D activities for the first nine months of the current consolidated fiscal year was ¥705 million.」
R&D expenses amounted to ¥705 million, up from ¥599 million in the same period of the previous year. - FY2024-Q2AdvancedAnnual report
「The amount of R&D activities for the first six months of the current consolidated fiscal year was ¥482 million.」
R&D expenses increased from ¥413 million in the same period of the previous year to ¥482 million, expanding the scale of spending on R&D activities. - FY2024-Q1AdvancedAnnual report
「The amount of R&D activities for the first quarter of the current consolidated fiscal year was ¥277 million.」
R&D expenses increased from ¥206 million in the same period of the previous year to ¥277 million, up 34.3% year on year. - FY2023AdvancedAnnual report
「The Group regards R&D as its highest priority in developing its business and conducts it with 82 R&D staff, including 24 PhD holders, out of a total workforce of 670 (as of 31 July 2023). R&D expenses for the current consolidated fiscal year amounted to ¥840 million, including personnel expenses for R&D staff,」
The number of R&D staff increased from 71 to 82, and R&D expenses increased from ¥766 million to ¥840 million. - FY2023-Q2AdvancedAnnual report
「The amount of R&D activities for the first six months of the current consolidated fiscal year was ¥413 million.」
R&D expenses amounted to ¥413 million, up from ¥310 million in the same period of the previous year. - FY2022AdvancedAnnual report
「The Group regards R&D as its highest priority in developing its business and conducts it with 71 R&D staff, including 19 PhD holders, out of a total workforce of 624 (as of 31 July 2022). R&D expenses for the current consolidated fiscal year amounted to ¥766 million, including personnel expenses for R&D staff,」
The number of R&D staff increased to 71, and R&D expenses rose to ¥766 million, expanding the R&D structure and spending scale. - FY2022-Q3AdvancedAnnual report
「The amount of R&D activities for the first nine months of the current consolidated fiscal year was ¥475 million.」
R&D expenses increased from ¥354 million in the same period of the previous year to ¥475 million, expanding the scale of spending on R&D activities. - FY2022-Q2AdvancedAnnual report
「The amount of R&D activities for the first six months of the current consolidated fiscal year was ¥310 million.」
R&D expenses increased from ¥210 million in the same period of the previous year to ¥310 million, up 47.1% year on year. - FY2022-Q1AdvancedAnnual report
「The amount of R&D activities for the first quarter of the current consolidated fiscal year was ¥145 million.」
R&D expenses increased from ¥97 million in the same period of the previous year to ¥145 million, up 48.5% year on year. - FY2021AdvancedAnnual report
「The Group regards R&D as its highest priority in developing its business and conducts it with 47 R&D staff, including 15 PhD holders, out of a total workforce of 293 (as of 31 July 2021). R&D expenses for the current consolidated fiscal year amounted to ¥522 million, including personnel expenses for R&D staff,」
The number of R&D staff increased to 47, and R&D expenses rose to ¥522 million from ¥437 million in the previous fiscal year. - FY2021-Q3AdvancedAnnual report
「The amount of R&D activity during the third quarter of the current consolidated cumulative period was ¥354 million.」
R&D expenses increased from ¥329 million in the same period of the previous year to ¥354 million, expanding the scale of spending on R&D activities. - FY2021-Q2Year-on-year decrease in research and development expensesAnnual report
「The amount of R&D activities for the first six months of the current consolidated fiscal year was ¥210 million.」
R&D activities have continued, but R&D expenses decreased from ¥228 million in the same period of the previous year to ¥210 million. - FY2021-Q1AdvancedAnnual report
「The amount of R&D activities for the first quarter of the current consolidated fiscal year was ¥97 million.」
R&D expenses increased from ¥77 million in the same period of the previous year to ¥97 million. - FY2020-Q3AdvancedAnnual report
「R&D expenditures for the nine months ended ... amounted to ¥329 million.」
R&D expenses increased from ¥227 million in the same period of the previous year to ¥329 million. - FY2020-Q2AdvancedAnnual report
「R&D expenditures for the six months ended ... amounted to ¥228 million.」
R&D expenses increased from ¥145 million in the same period of the previous year to ¥228 million. - FY2020-Q1RestatedAnnual report
「Group-wide R&D expenditures for the three months ended ... amounted to ¥77 million.」
R&D activities continued, with expenditures for the three months ended disclosed as ¥77 million. - FY2019AdvancedAnnual report
「R&D expenses for the fiscal year under review totaled ¥317.162 million, including personnel expenses for R&D staff. This amount includes ¥10.078 million in basic research expenses that cannot be allocated to individual segments.」
R&D expenses increased from ¥274.243 million in the previous fiscal year to ¥317.162 million, indicating an expansion in the scale of annual R&D activities. - FY2019-Q3RestatedAnnual report
「R&D expenditures for the nine months ended ... amounted to ¥227 million.」
R&D activities continued, with expenditures for the nine months ended disclosed as ¥227 million. - FY2019-Q2RestatedAnnual report
「R&D expenditures for the six months ended ... amounted to ¥145 million.」
R&D activities continued, with expenditures for the six months ended disclosed as ¥145 million. - FY2019-Q1RestatedAnnual report
「Group-wide R&D expenditures for the three months ended ... amounted to ¥71 million.」
R&D activities continued, with expenditures for the three months ended disclosed as ¥71 million. - FY2018-Q3RestatedAnnual report
「R&D expenditures for the nine months ended ... amounted to ¥199 million.」
R&D activities continued, with expenditures for the nine months ended disclosed as ¥199 million. - FY2018-Q2RestatedAnnual report
「R&D expenditures for the six months ended ... amounted to ¥121 million.」
R&D activities continued, with expenditures for the six months ended disclosed as ¥121 million. - FY2018-Q1RestatedAnnual report
「Group-wide R&D expenditures for the three months ended ... amounted to ¥58 million.」
R&D activities continued, with expenditures for the three months ended disclosed as ¥58 million. - FY2017-Q3RestatedAnnual report
「R&D expenditures for the nine months ended ... amounted to ¥176 million.」
R&D activities continued, with expenditures for the nine months ended disclosed as ¥176 million. - FY2017-Q2RestatedAnnual report
「R&D expenditures for the six months ended ... amounted to ¥123 million.」
R&D activities continued, with expenditures for the six months ended disclosed as ¥123 million. - FY2017-Q1RestatedAnnual report
「Group-wide R&D expenditures for the three months ended ... amounted to ¥64 million.」
R&D activities continued, with expenditures for the quarter disclosed as ¥64 million. - FY2016-Q3First statedAnnual report
「R&D expenditures for the nine months ended ... amounted to ¥238 million.」
R&D expenditures for the nine months ended ... were disclosed as ¥238 million.